

## PRESS RELEASE

### **Elanix Biotechnologies's Partner Transwell Biotech Starts First Clinical Study with Progenitor Cell Treatment for Skin Graft Wounds**

#### **First Patient Treated in Phase I/II TWB-103 Trial**

**Nyon, Switzerland and Potsdam, Germany, July 20, 2017** -- [Elanix Biotechnologies AG](#) (FRA: ELN), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, announced today the treatment of the first patient in a Phase I/II clinical trial with TWB-103 in adults with skin graft donor site wounds (DSW). The study is being conducted in Taiwan and Japan with partner Transwell Biotech Co., Ltd, subsidiary of Easywell Biomedicals. TWB-103 is a novel gel formulation developed by Transwell Biotech, using skin fibroblast progenitor cells provided by Elanix.

The study will be conducted at the Tri-Service General Hospital in Taipei as well as the Tokyo Medical University Hospital and the Nippon Medical School Hospital in Tokyo. The aim is to compare safety and efficacy of TWB-103 with standard of care Tegaderm™ skin dressing to Tegaderm™ alone in 30 individuals. Primary objectives are safety and healing time from DSW creation to 100% re-epithelialization.

“The start of the first human studies of TWB-103 is a significant milestone in our plan to build a regenerative medicine franchise in acute wound healing based on our proprietary progenitor cell technology. This gets us one step closer to introducing an acute wound care treatment to the market which could benefit over two million patients worldwide that are hospitalised for burns annually,” stated Tomas Svoboda, CEO of Elanix Biotechnologies. “The team at Transwell has been very efficient in advancing a solid clinical strategy in Asia.”

“TWB-103 is a key part of our future wound-care pipeline. The first patient has now been treated and this clinical milestone is a major step for Transwell Biotech and one that we intend to expand to other Asian markets this year,” said Dr. Sean Chen, General Manager of Transwell Biotech.

**Elanix Biotechnologies AG** (FRA: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix is headquartered in Nyon, Switzerland, with its registered office in Potsdam, Germany, and listed on the Frankfurt Stock Exchange under the symbol ELN. For more information and updates, visit [www.elanixbiotechnologies.com](http://www.elanixbiotechnologies.com).

**Transwell Biotech Co., Ltd** (subsidiary of Easywell Biomedicals) is based in Taipei City, Taiwan and focuses on regenerative medicine involving the application of progenitor skin cells on wounds. The company develops and commercializes therapeutic and supporting care products for patients with various types and stages of wounds, as well as providing wound-care therapy services during and after injury recovery.

**Press Contacts:**

Elanix Biotechnologies AG

Tomas Svoboda, CEO

Tel: +41 22 363 66 40

investor.relations@elanix-bt.com

Halsin Partners

Mike Sinclair

Tel: +44 (0)20 7318 2955

msinclair@halsin.com

**Disclaimer / Forward-looking statements:**

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.